Avadel Pharmaceuticals Plc Is A Biopharmaceutical Company Based In Dublinirelandspecializing In The Development Of Innovative Pharmaceutical Productsformerly Known As Flamel Technologies Sathe Company Rebranded In January 2017Avadel Focuses On The Specialty Pharmaceutical Sectorparticularly In Neurology And Sleep Medicinewith A Mission To Transform Medicines To Improve Lives The Company S Lead Productlumryzis An Fda Approved Treatment For Idiopathic Hypersomnia And Is Currently In Phase 3 Clinical Trials For Narcolepsy Related Symptomsavadel Is Dedicated To Addressing Unmet Medical Needs In Neurological And Sleep Disorders Through Advanced Pharmaceutical Formulation Technologiesas Of January 2024Avadel Pharmaceuticals Has A Market Capitalization Of Approximately $95 2 Million And Reported A Revenue Of $76 4 Million In 2023
